Table 2.
Expression profiles of cell adhesion molecule 1, signal transducer and activator of transcription 3, and human epidermal growth factor receptor in serous cystadenoma, serous borderline tumor, low-grade serous ovarian carcinoma, and high-grade serous ovarian carcinoma patients.
| CADM1 n (%) | HER2 n (%) | STAT3 n (%) | ||||||||
| Clinical classification | n (total) | Negative | Positive | P-value | Negative | Positive | P value | Negative | Positive | P value |
| Serous cystadenoma | 20 | 0 (0) | 20 (100) | < .0001 | 20 (100) | 0 (0) | .002 | 18 (90) | 2 (10) | < .0001 |
| SBT | 30 | 5 (16.67) | 25 (83.33) | 28 (93.33) | 2 (6.67) | 22 (73.33) | 8 (26.67) | |||
| LGSC | 50 | 22 (44) | 28 (56) | 44 (88) | 6 (12) | 24 (48) | 26 (52) | |||
| HGSC | 80 | 58 (72.5) | 22 (27.5) | 57 (71.25) | 23 (28.75) | 16 (20) | 64 (80) | |||
Data are presented as n (%). Comparisons were performed using the Chi-squared test. P < .05 was considered statistically significant.
CADM1 = cell adhesion molecule 1, HER2 = human epidermal growth factor receptor 2, HGSC = high-grade serous ovarian carcinoma, LGSC = low-grade serous ovarian carcinoma, SBT = serous borderline tumor, STAT3 = signal transducer and activator of transcription 3.